Department of Veterinary Medical Science, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
J Vet Pharmacol Ther. 2021 Sep;44(5):776-782. doi: 10.1111/jvp.12977. Epub 2021 May 12.
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
本研究旨在确定健康成年杜洛克猪口服(OS;20mg/kg)和复方静脉内(IV;5.5mg/kg)给予加巴喷丁的药代动力学(PK)。将受试对象随机分为 IV 和 OS 加巴喷丁交叉设计组,两种药物给药之间至少有 14 天的洗脱期。在给予加巴喷丁之前和之后的 24 小时内的不同时间点采集血样,并将收获的血浆储存于-80°C,直至分析。使用先前验证的液相色谱/串联质谱法来定量加巴喷丁的浓度,并用非线性混合效应(群体)分析来拟合时间-浓度数据的房室模型。静脉内给药后,两室模型最适合数据拟合。在 IV 给药后,中央室容积和清除率以及稳态和终末半衰期时计算的分布容积的典型值分别为 170ml/kg、1.2ml/(kg*min)和 594ml/kg 和 360min。对于口服途径,吸收半衰期、估计的最大血浆浓度和达到最大血浆浓度的时间分别为 58min、9155ng/ml 和 194min。估计的口服生物利用度为 47%。所有受试对象在静脉内给药后均观察到短暂的镇静(约 15min),表现为胸骨或侧卧。没有观察到不良反应。基于该研究结果的模拟表明,首剂口服加巴喷丁 15mg/kg,随后每 8 小时给予 8.5mg/kg 的剂量,可在猪体内达到并维持 5 至 8μg/ml 的血浆浓度。